Our research aims to address the molecular mechanisms underlying the oncogenic action of the MYC transcription factor and to exploit them for pre-clinical development of targeted therapies. Through a combination of mechanism-driven hypotheses and high-throughput screens, we identified diverse synthetic-lethal interactions that allow selective killing of MYCdriven cancer cells by targeted genetic or pharmacological interventions. Essential mechanistic insight is provided by the alterations in mRNA expression and processing profiles elicited by combined MYC activation and drug treatment. In order to map these alterations, we use next-generation sequencing (NGS)-based genomic approaches, such as RNA-seq or ChIP-seq.
We seek to recruit an ambitious, motivated, team-oriented scientist with a PhD in computational biology, or related. The successful candidate will be involved in the computational analysis of NGS datasets produced in the laboratory, in close collaboration with experimental scientists in the group. He/she will benefit from a strong, integrative computational community in our institute. Special attention will be given to MYC and drug-induced alterations in gene expression at both the transcriptional and post-transcriptional levels (e.g. alternative splicing, degradation, translation) which ultimately impact protein production and cell fate.
Advanced proficiency in R for end-to-end RNA-seq analysis, including: